WO2010044108A3 - Controlled release formulations of ropinirole - Google Patents

Controlled release formulations of ropinirole Download PDF

Info

Publication number
WO2010044108A3
WO2010044108A3 PCT/IN2009/000592 IN2009000592W WO2010044108A3 WO 2010044108 A3 WO2010044108 A3 WO 2010044108A3 IN 2009000592 W IN2009000592 W IN 2009000592W WO 2010044108 A3 WO2010044108 A3 WO 2010044108A3
Authority
WO
WIPO (PCT)
Prior art keywords
ropinirole
controlled release
release formulations
swelling
dosage forms
Prior art date
Application number
PCT/IN2009/000592
Other languages
French (fr)
Other versions
WO2010044108A2 (en
Inventor
Pratibha Sudhir Pilgaonkar
Maharukh Tehmasp Rustomjee
Anilkumar Surendrakumar Gandhi
Atul A. Kelkar
Original Assignee
Rubicon Research Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Research Private Limited filed Critical Rubicon Research Private Limited
Publication of WO2010044108A2 publication Critical patent/WO2010044108A2/en
Publication of WO2010044108A3 publication Critical patent/WO2010044108A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The present invention relates to non-swelling controlled release dosage forms comprising a therapeutically effective amount of ropinirole or a pharmaceutically acceptable salt thereof and at least one non-swelling release retardant. Further, the non-swelling controlled release dosage forms of the present invention provide effective plasma levels of ropinirole over a period of up to about 24 hours or more after administration.
PCT/IN2009/000592 2008-10-17 2009-10-16 Controlled release formulations of ropinirole WO2010044108A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2235MU2008 2008-10-17
IN2235/MUM/2008 2008-10-17

Publications (2)

Publication Number Publication Date
WO2010044108A2 WO2010044108A2 (en) 2010-04-22
WO2010044108A3 true WO2010044108A3 (en) 2010-07-15

Family

ID=42034625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000592 WO2010044108A2 (en) 2008-10-17 2009-10-16 Controlled release formulations of ropinirole

Country Status (1)

Country Link
WO (1) WO2010044108A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20130189A1 (en) * 2013-08-05 2015-02-06 Valpharma Internat S P A A PHARMACEUTICAL COMPOSITION CONTAINING ADMINISTABLE ROPINIROL HCL BY ORAL AND PRODUCTION METHOD.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040247676A1 (en) * 2001-10-18 2004-12-09 Atkinson Gillian Frances Use of multi-layer controlled-release tablet comprising ropinirole for the manufacture of medicament for the treatment of fibromyalgia
US20070059365A1 (en) * 2003-08-22 2007-03-15 Pollock Peta E Novel formulation of ropinirole
WO2007036952A2 (en) * 2005-07-01 2007-04-05 Rubicon Research Pvt Ltd. Novel sustained release dosage form
WO2009023761A2 (en) * 2007-08-14 2009-02-19 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising ropinirole

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8712073D0 (en) 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
AR030557A1 (en) 2000-04-14 2003-08-27 Jagotec Ag A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD
US6277875B1 (en) 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040247676A1 (en) * 2001-10-18 2004-12-09 Atkinson Gillian Frances Use of multi-layer controlled-release tablet comprising ropinirole for the manufacture of medicament for the treatment of fibromyalgia
US20070059365A1 (en) * 2003-08-22 2007-03-15 Pollock Peta E Novel formulation of ropinirole
WO2007036952A2 (en) * 2005-07-01 2007-04-05 Rubicon Research Pvt Ltd. Novel sustained release dosage form
WO2009023761A2 (en) * 2007-08-14 2009-02-19 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising ropinirole

Also Published As

Publication number Publication date
WO2010044108A2 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
WO2009017837A3 (en) Sublingual fentanyl spray
WO2007087431A3 (en) Sublingual fentanyl spray
WO2008137787A3 (en) Combination therapy with a compound acting as a platelet adp receptor inhibitor
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
MY146574A (en) Stabilized pharmaceutical compositions comprising fesoterodine
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2009047723A3 (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
WO2007135527A3 (en) Benzimidazolyl compounds
WO2009058798A3 (en) Orally disintegrated dosage form
UA92641C2 (en) Pharmaceutical composition comprising amlodipine and losartan
WO2011014587A3 (en) Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
WO2009145989A3 (en) Aminoalkylphenyl antagonists of prostaglandin d2 receptors
WO2012051559A3 (en) Compositions and methods of treating pulmonary hypertension
WO2010132757A3 (en) Antibacterial aminoglycoside analogs
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
WO2010132765A3 (en) Antibacterial aminoglycoside analogs
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
BRPI0817275A2 (en) Pharmaceutical combination of aliskiren and valsartan
TN2010000135A1 (en) Galenical formulations of organic compounds
WO2007109288A3 (en) Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
WO2007113857A3 (en) Modified release clopidogrel formulation
WO2007145863A3 (en) Sustained release formulation of naltrexone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09804156

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09804156

Country of ref document: EP

Kind code of ref document: A2